PE20220001A1 - Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales - Google Patents
Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentalesInfo
- Publication number
- PE20220001A1 PE20220001A1 PE2021001359A PE2021001359A PE20220001A1 PE 20220001 A1 PE20220001 A1 PE 20220001A1 PE 2021001359 A PE2021001359 A PE 2021001359A PE 2021001359 A PE2021001359 A PE 2021001359A PE 20220001 A1 PE20220001 A1 PE 20220001A1
- Authority
- PE
- Peru
- Prior art keywords
- dmt
- meo
- methoxy
- treatment
- dimethyltriptamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19158806 | 2019-02-22 | ||
PCT/EP2020/054804 WO2020169851A1 (fr) | 2019-02-22 | 2020-02-24 | Compositions comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) pour une utilisation dans le traitement de troubles mentaux |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20220001A1 true PE20220001A1 (es) | 2022-01-05 |
Family
ID=65529518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001359A PE20220001A1 (es) | 2019-02-22 | 2020-02-24 | Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220031662A1 (fr) |
EP (1) | EP3927338A1 (fr) |
JP (1) | JP2022522659A (fr) |
KR (1) | KR20210154967A (fr) |
CN (1) | CN114423422A (fr) |
AU (1) | AU2020225766A1 (fr) |
BR (1) | BR112021016169A2 (fr) |
CA (1) | CA3130180A1 (fr) |
CL (1) | CL2021002173A1 (fr) |
CO (1) | CO2021010883A2 (fr) |
CR (1) | CR20210436A (fr) |
DO (1) | DOP2021000175A (fr) |
EA (1) | EA202192319A1 (fr) |
IL (1) | IL285539A (fr) |
MA (1) | MA55022A (fr) |
MX (1) | MX2021009942A (fr) |
NI (1) | NI202100074A (fr) |
PE (1) | PE20220001A1 (fr) |
WO (1) | WO2020169851A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022521789A (ja) | 2019-02-27 | 2022-04-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脳障害を治療するためのアゼピノ-インドール及び他の複素環化合物 |
MX2021010198A (es) | 2019-02-27 | 2021-09-21 | Univ California | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. |
GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
PT3844147T (pt) | 2019-11-07 | 2022-07-04 | Small Pharma Ltd | Compostos |
MX2022014605A (es) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Derivados de triptamina deuterada y metodos de uso. |
US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
JP2023530292A (ja) | 2020-06-12 | 2023-07-14 | ベックリー・サイテック・リミテッド | 5-メトキシ-n,n-ジメチルトリプタミンの安息香酸塩を含む組成物 |
EP4192451A1 (fr) * | 2020-08-05 | 2023-06-14 | Universitätsspital Basel | Procédé d'administration de dmt intraveineux pour psychothérapie assistée par dmt |
US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
WO2022189662A1 (fr) | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions et méthodes pour traiter des addictions comprenant de la 5-meo-dmt |
AU2022267240A1 (en) | 2021-04-26 | 2023-11-23 | Atai Therapeutics, Inc. | Novel n,n-dimethyltryptamine compositions and methods |
US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
WO2023111544A2 (fr) * | 2021-12-13 | 2023-06-22 | Beckley Psytech Limited | Sel de benzoate de 5-méthoxy-n,n-diméthyltryptamine |
WO2023114557A2 (fr) * | 2021-12-17 | 2023-06-22 | Journey Colab Corp. | Procédés de traitement de troubles de l'usage de substances à l'aide de 5-meo-dmt |
AU2022425541A1 (en) | 2021-12-30 | 2024-06-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
FI4313945T3 (fi) | 2022-03-27 | 2024-05-23 | Gh Res Ireland Limited | 5-meo-dmt:n kiteinen hydrobromidisuola |
WO2023186827A1 (fr) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-méthoxy-n, n-diméthyltryptamine pour le traitement de la dépression post-partum |
WO2023186806A1 (fr) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-méthoxy-n,n-diméthyltryptamine pour le traitement d'un trouble bipolaire |
GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
CN103816150A (zh) * | 2014-03-14 | 2014-05-28 | 兰州理工大学 | 山蚂蝗生物碱单体成分的用途 |
WO2018195455A1 (fr) * | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Évaluation et traitement de sujets réactifs aux agents psychédéliques |
-
2020
- 2020-02-24 CR CR20210436A patent/CR20210436A/es unknown
- 2020-02-24 WO PCT/EP2020/054804 patent/WO2020169851A1/fr unknown
- 2020-02-24 MX MX2021009942A patent/MX2021009942A/es unknown
- 2020-02-24 KR KR1020217030216A patent/KR20210154967A/ko unknown
- 2020-02-24 MA MA055022A patent/MA55022A/fr unknown
- 2020-02-24 BR BR112021016169A patent/BR112021016169A2/pt unknown
- 2020-02-24 AU AU2020225766A patent/AU2020225766A1/en active Pending
- 2020-02-24 EA EA202192319A patent/EA202192319A1/ru unknown
- 2020-02-24 US US17/431,634 patent/US20220031662A1/en not_active Abandoned
- 2020-02-24 PE PE2021001359A patent/PE20220001A1/es unknown
- 2020-02-24 CN CN202080030434.XA patent/CN114423422A/zh active Pending
- 2020-02-24 CA CA3130180A patent/CA3130180A1/fr active Pending
- 2020-02-24 EP EP20710060.3A patent/EP3927338A1/fr active Pending
- 2020-02-24 JP JP2021549460A patent/JP2022522659A/ja active Pending
-
2021
- 2021-08-11 IL IL285539A patent/IL285539A/en unknown
- 2021-08-16 CL CL2021002173A patent/CL2021002173A1/es unknown
- 2021-08-18 CO CONC2021/0010883A patent/CO2021010883A2/es unknown
- 2021-08-20 DO DO2021000175A patent/DOP2021000175A/es unknown
- 2021-08-20 NI NI202100074A patent/NI202100074A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210154967A (ko) | 2021-12-21 |
JP2022522659A (ja) | 2022-04-20 |
MX2021009942A (es) | 2021-12-10 |
NI202100074A (es) | 2021-12-06 |
IL285539A (en) | 2021-09-30 |
AU2020225766A1 (en) | 2021-08-19 |
DOP2021000175A (es) | 2021-11-21 |
CL2021002173A1 (es) | 2022-01-28 |
CO2021010883A2 (es) | 2022-01-17 |
CR20210436A (es) | 2021-11-02 |
WO2020169851A1 (fr) | 2020-08-27 |
CA3130180A1 (fr) | 2020-08-27 |
BR112021016169A2 (pt) | 2021-11-03 |
EP3927338A1 (fr) | 2021-12-29 |
CN114423422A (zh) | 2022-04-29 |
US20220031662A1 (en) | 2022-02-03 |
MA55022A (fr) | 2021-12-29 |
EA202192319A1 (ru) | 2021-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20220001A1 (es) | Composiciones que comprenden 5-metoxi-n,n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales | |
CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
CL2019001433A1 (es) | Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684) | |
CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
AR090601A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos | |
JP2016518387A5 (fr) | ||
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
MA40769A (fr) | Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
SV2017005595A (es) | Unidad de dosificacion orodispersable que contiene un componente estetrol | |
CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
AR086422A1 (es) | Metodo para el tratamiento de tumores solidos avanzados, volasertib | |
CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
ES2663836T3 (es) | Carboxamidas de quinolina para su uso en el tratamiento de leucemia | |
CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
CL2021001635A1 (es) | Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a |